<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9134">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772889</url>
  </required_header>
  <id_info>
    <org_study_id>111738</org_study_id>
    <nct_id>NCT00772889</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly</brief_title>
  <official_title>Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind clinical trial is to evaluate the safety and
      immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in the elderly.
      Subjects were previously vaccinated (NCT00529516).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</measure>
    <time_frame>Day 0-6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Grade 3 ecchymosis, redness and swelling were ≥ 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was &gt;20 mm for ecchymosis, redness and swelling.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration was defined as number of days with any grade of local symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to the study vaccination, grade 3 was defined as a general symptom that prevented normal activity. Related arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever were defined as general symptoms assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited General AEs</measure>
    <time_frame>Day 0-6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration was defined as number of days with any grade of general symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</measure>
    <time_frame>Day 0-20</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade. Grade 3 was defined as an unsolicited symptom that prevented normal activity. Related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) During Day 0 to Day 20</measure>
    <time_frame>Day 0-20</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases From Day 0 to Day 20</measure>
    <time_frame>Day 0-20</time_frame>
    <safety_issue>No</safety_issue>
    <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20</measure>
    <time_frame>Day 0-20</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) Between Day 21 and Day 179</measure>
    <time_frame>Day 21-179</time_frame>
    <safety_issue>No</safety_issue>
    <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases Between Day 21 and Day 364</measure>
    <time_frame>Day 21-364.</time_frame>
    <safety_issue>No</safety_issue>
    <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemagglutination Inhibition (HI) Antibody Titers</measure>
    <time_frame>Day 0-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titres (GMTs) per separate vaccine strain. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seropositive to HI Antibodies</measure>
    <time_frame>Day 0-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seropositive subject was defined as a subject with antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroprotected by HI Antibodies</measure>
    <time_frame>Day 0-21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects Seroconverted to HI Antibodies</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors (SCF)</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 21 to Day 364</measure>
    <time_frame>Day 21-364</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">971</enrollment>
  <condition>Influenza Infection</condition>
  <arm_group>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix young Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine GSK2186877A</intervention_name>
    <description>One intramuscularly injection at Day 0</description>
    <arm_group_label>New generation influenza vaccine GSK2186877A Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' Fluarix™</intervention_name>
    <description>One intramuscularly injection at Day 0</description>
    <arm_group_label>Fluarix elderly Group</arm_group_label>
    <arm_group_label>Fluarix young Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female subject previously enrolled in study 109821 (NCT 00529516) in the &gt;=
             65 years and 18-41 years of age groups and having received the study vaccine.

          -  Subjects of whom the investigator believes that they can and will comply with the
             requirements of the protocol. Specific attention should be given to the compliance
             potential of subjects with suspected or known drug or alcohol abuse.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by medical history
             and clinical examination before entering into the study

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2
             months after completion of the vaccination series.

        Exclusion Criteria:

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines)
             or 4 weeks (for live vaccines) prior to enrolment in this study.

          -  Planned administration of a vaccine not foreseen by the study protocol up to 30 days
             after vaccination.

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period.

          -  Any vaccination against influenza since January 2008 with any seasonal influenza
             vaccine.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of hypersensitivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccines.

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or pre-existing
             laboratory screening tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of the study vaccine or planned administration during
             the study period.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days prior to vaccination, or planned use during the study
             period.

          -  Any medical conditions in which intramuscular injections are contraindicated.

          -  Pregnant or lactating females.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milford</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Messkirch</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88605</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haag</city>
        <state>Bayern</state>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoehenkirchen-Siegertsbrunn</city>
        <state>Bayern</state>
        <zip>85635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langquaid</city>
        <state>Bayern</state>
        <zip>84085</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12687</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>N-1357</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fredrikstad</city>
        <zip>N-1601</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haugesund</city>
        <zip>5528</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skien</city>
        <zip>3717</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>October 25, 2012</lastchanged_date>
  <firstreceived_date>October 10, 2008</firstreceived_date>
  <firstreceived_results_date>March 29, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="P3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="375"/>
                <participants group_id="P2" count="393"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed at Day 21</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="390"/>
                <participants group_id="P3" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="375"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="375"/>
                <measurement group_id="B2" value="393"/>
                <measurement group_id="B3" value="203"/>
                <measurement group_id="B4" value="971"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74.4" spread="5.23"/>
                <measurement group_id="B2" value="74.7" spread="5.74"/>
                <measurement group_id="B3" value="32.4" spread="6.78"/>
                <measurement group_id="B4" value="65.7" spread="18.10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="203"/>
                <measurement group_id="B3" value="118"/>
                <measurement group_id="B4" value="511"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="185"/>
                <measurement group_id="B2" value="190"/>
                <measurement group_id="B3" value="85"/>
                <measurement group_id="B4" value="460"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
        <description>Grade 3 ecchymosis, redness and swelling were ≥ 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was &gt;20 mm for ecchymosis, redness and swelling.</description>
        <time_frame>Day 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="392"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)</title>
            <description>Grade 3 ecchymosis, redness and swelling were ≥ 100 millimeters (mm) and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was &gt;20 mm for ecchymosis, redness and swelling.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="122"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited Local AEs</title>
        <description>Duration was defined as number of days with any grade of local symptoms.</description>
        <time_frame>Day 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="122"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Solicited Local AEs</title>
            <description>Duration was defined as number of days with any grade of local symptoms.</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Ecchymosis (N=2; 3; 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.5" lower_limit="6.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="5.0" lower_limit="3.0" upper_limit="5.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain (N=159; 49; 122)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness (N=57; 9; 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling (N=23; 6; 7)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
        <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to the study vaccination, grade 3 was defined as a general symptom that prevented normal activity. Related arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever were defined as general symptoms assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="392"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs</title>
            <description>Any fever was defined as oral temperature ≥38.0 degree centigrade (°C), grade 3 fever was oral temperature ≥ 39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relationship to the study vaccination, grade 3 was defined as a general symptom that prevented normal activity. Related arthralgia, fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever were defined as general symptoms assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related gastrointestinal symptoms</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="38"/>
                  <measurement group_id="O3" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited General AEs</title>
        <description>Duration was defined as number of days with any grade of general symptoms.</description>
        <time_frame>Day 0-6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="72"/>
                  <measurement group_id="O2" value="38"/>
                  <measurement group_id="O3" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Duration of Solicited General AEs</title>
            <description>Duration was defined as number of days with any grade of general symptoms.</description>
            <units>Days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Arthralgia (N=44; 20; 11)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (N=72; 37; 39)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal symptoms (N=26; 18; 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (N=54; 38; 31)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                  <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (N=68; 33; 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering (32; 16; 10)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="7.0"/>
                  <measurement group_id="O2" value="1.5" lower_limit="1.0" upper_limit="5.0"/>
                  <measurement group_id="O3" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (N=3; 1; 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  <measurement group_id="O3" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade. Grade 3 was defined as an unsolicited symptom that prevented normal activity. Related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade. Grade 3 was defined as an unsolicited symptom that prevented normal activity. Related was an event assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) During Day 0 to Day 20</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) During Day 0 to Day 20</title>
            <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases From Day 0 to Day 20</title>
        <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade.</description>
        <time_frame>Day 0-20</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases From Day 0 to Day 20</title>
            <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 0-20</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 0 to Day 20</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) Between Day 21 and Day 179</title>
        <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 21-179</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) Between Day 21 and Day 179</title>
            <description>For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                  <measurement group_id="O2" value="111"/>
                  <measurement group_id="O3" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="26"/>
                  <measurement group_id="O3" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases Between Day 21 and Day 364</title>
        <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 21-364.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting AEs of Specific Interest (AESI) Including Autoimmune Diseases Between Day 21 and Day 364</title>
            <description>AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom regardless of intensity grade, grade 3 was defined as a symptom that prevented normal activity and related was a general symptom assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AESI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 AESI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related AESI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Haemagglutination Inhibition (HI) Antibody Titers</title>
        <description>Antibody titers were expressed as Geometric mean titres (GMTs) per separate vaccine strain. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 0-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Haemagglutination Inhibition (HI) Antibody Titers</title>
            <description>Antibody titers were expressed as Geometric mean titres (GMTs) per separate vaccine strain. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
            <units>titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.5" lower_limit="25.7" upper_limit="31.5"/>
                  <measurement group_id="O2" value="22.9" lower_limit="20.7" upper_limit="25.3"/>
                  <measurement group_id="O3" value="52.8" lower_limit="44.6" upper_limit="62.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane strain at Day 21(N=367; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.8" lower_limit="64.7" upper_limit="77.4"/>
                  <measurement group_id="O2" value="51.9" lower_limit="47.0" upper_limit="57.2"/>
                  <measurement group_id="O3" value="112.5" lower_limit="98.4" upper_limit="128.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48.9" lower_limit="43.5" upper_limit="54.8"/>
                  <measurement group_id="O2" value="29.2" lower_limit="25.7" upper_limit="33.1"/>
                  <measurement group_id="O3" value="29.2" lower_limit="25.1" upper_limit="34.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="331.3" lower_limit="296.7" upper_limit="370.0"/>
                  <measurement group_id="O2" value="149.2" lower_limit="131.1" upper_limit="169.9"/>
                  <measurement group_id="O3" value="161.7" lower_limit="137.8" upper_limit="189.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="169.1" lower_limit="153.2" upper_limit="186.7"/>
                  <measurement group_id="O2" value="157.4" lower_limit="143.2" upper_limit="173.1"/>
                  <measurement group_id="O3" value="196.4" lower_limit="167.3" upper_limit="230.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="576.5" lower_limit="526.5" upper_limit="631.1"/>
                  <measurement group_id="O2" value="463.5" lower_limit="422.0" upper_limit="509.1"/>
                  <measurement group_id="O3" value="765.2" lower_limit="682.3" upper_limit="858.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seropositive to HI Antibodies</title>
        <description>A seropositive subject was defined as a subject with antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 0-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Subjects Seropositive to HI Antibodies</title>
            <description>A seropositive subject was defined as a subject with antibody titer greater than or equal to the cut-off value i.e ≥ 1:10. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="336"/>
                  <measurement group_id="O2" value="315"/>
                  <measurement group_id="O3" value="186"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane strain at Day 21 (N=367; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="364"/>
                  <measurement group_id="O2" value="366"/>
                  <measurement group_id="O3" value="193"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="344"/>
                  <measurement group_id="O2" value="320"/>
                  <measurement group_id="O3" value="167"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="368"/>
                  <measurement group_id="O3" value="191"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="366"/>
                  <measurement group_id="O2" value="374"/>
                  <measurement group_id="O3" value="192"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroprotected by HI Antibodies</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>Day 0-21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Subjects Seroprotected by HI Antibodies</title>
            <description>A seroprotected subject was defined as a subject with a serum HI titer ≥ 1:40 that usually is accepted as indicating protection. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="171"/>
                  <measurement group_id="O2" value="142"/>
                  <measurement group_id="O3" value="137"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane strain at Day 21 (N=367; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="276"/>
                  <measurement group_id="O3" value="179"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="247"/>
                  <measurement group_id="O2" value="178"/>
                  <measurement group_id="O3" value="102"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="361"/>
                  <measurement group_id="O2" value="341"/>
                  <measurement group_id="O3" value="181"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain at Day 0 (N=366; 374; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="359"/>
                  <measurement group_id="O2" value="363"/>
                  <measurement group_id="O3" value="186"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain at Day 21 (N=368; 375; 194)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="368"/>
                  <measurement group_id="O2" value="375"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects Seroconverted to HI Antibodies</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="366"/>
                  <measurement group_id="O2" value="374"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Subjects Seroconverted to HI Antibodies</title>
            <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                  <measurement group_id="O2" value="94"/>
                  <measurement group_id="O3" value="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="285"/>
                  <measurement group_id="O2" value="228"/>
                  <measurement group_id="O3" value="124"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="168"/>
                  <measurement group_id="O2" value="140"/>
                  <measurement group_id="O3" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors (SCF)</title>
        <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According-to-Protocol (ATP) immunogenicity cohort . The cohort included all evaluable subjects for whom data concerning immunogenicity at were available.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="366"/>
                  <measurement group_id="O2" value="374"/>
                  <measurement group_id="O3" value="194"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HI Antibody Seroconversion Factors (SCF)</title>
            <description>SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Brisbane, A/Uruguay and B/Brisbane antigens.</description>
            <units>fold increase</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Brisbane strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.5" lower_limit="2.3" upper_limit="2.7"/>
                  <measurement group_id="O2" value="2.3" lower_limit="2.1" upper_limit="2.5"/>
                  <measurement group_id="O3" value="2.1" lower_limit="1.9" upper_limit="2.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Uruguay strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.8" lower_limit="6.1" upper_limit="7.5"/>
                  <measurement group_id="O2" value="5.1" lower_limit="4.6" upper_limit="5.7"/>
                  <measurement group_id="O3" value="5.5" lower_limit="4.7" upper_limit="6.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" lower_limit="3.1" upper_limit="3.7"/>
                  <measurement group_id="O2" value="2.9" lower_limit="2.7" upper_limit="3.2"/>
                  <measurement group_id="O3" value="3.9" lower_limit="3.3" upper_limit="4.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 21 to Day 364</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Day 21-364</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>New Generation Influenza Vaccine GSK2186877A Group</title>
            <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Elderly Group</title>
            <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
          </group>
          <group group_id="O3">
            <title>Fluarix Young Group</title>
            <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="375"/>
                  <measurement group_id="O2" value="393"/>
                  <measurement group_id="O3" value="203"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) From Day 21 to Day 364</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was an event assessed by the investigator as causally related to the study vaccination.</description>
            <units>subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were assessed from Day 0 to 20 and from Day 21 to 364. Systematically assessed frequent adverse events (AEs) and non-systematically assessed frequent AEs were assessed during 7 day and 21 day post-vaccination period respectively.</time_frame>
      <desc>For the frequent adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>New Generation Influenza Vaccine GSK2186877A Group</title>
          <description>Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Elderly Group</title>
          <description>Subjects aged ≥66 years received one dose of Fluarix vaccine.</description>
        </group>
        <group group_id="E3">
          <title>Fluarix Young Group</title>
          <description>Subjects aged 19-43 years received one dose of Fluarix vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Factor XIII deficiency</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scleroderma</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Aesthesioneuroblastoma</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <description>SAE was assessed from Day 0 to Day 20</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Femoral arterial stenosis</sub_title>
                <description>SAE was assessed from Day 21-364</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="159" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="122" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="375"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="392"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
